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OBJECTIVES The aim of the study was to evaluate the impact of preprocedural Thrombolysis In
Myocardial Infarction (TIMI) flow on one-year mortality in patients with ST-segment
elevation myocardial infarction (STEMI) treated by primary angioplasty.
BACKGROUND Although there is an excellent outcome conferred by primary angioplasty in patients with
STEMI, the prognostic role of early recanalization in these patients has yet to be investigated.
METHODS Our population is composed of 1,791 patients with acute myocardial infarction treated by
primary angioplasty at our institution from 1994 to 2001. All angiographic, clinical, and
follow-up data were prospectively collected. According to the TIMI risk score, patients were
stratified in low- and high-risk groups.
RESULTS Preprocedural TIMI flow was related to postprocedural TIMI flow grade 3 (p  0.002),
myocardial blush grade 2 to 3 (p  0.001), enzymatic infarct size (p  0.001), predischarge
ejection fraction (p 0.001), and one-year mortality (p 0.05). Multivariate analysis showed
that preprocedural TIMI flow grade 3 was an independent predictor of one-year survival in
high-risk patients (p  0.05).
CONCLUSIONS This study shows that preprocedural TIMI flow grade 3 is an independent predictor of
one-year survival in high-risk patients with acute myocardial infarction treated by primary
angioplasty. These data suggest that all efforts should be made to obtain early and optimal
restoration of antegrade flow, particularly in high-risk patients and when transportation to
tertiary centers, with a conceivable further time delay, is required. (J Am Coll Cardiol 2004;
43:1363–7) © 2004 by the American College of Cardiology Foundationp
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(rimary angioplasty has been shown to improve the out-
ome of patients with ST-segment elevation myocardial
nfarction (STEMI), in comparison with thrombolysis (1–
). Nevertheless, the time delay required for transportation
o a center with angioplasty facilities represents a major
rawback of primary angioplasty and may potentially result
n a worse outcome, particularly in high-risk patients (7).
The aim of this study was to investigate the prognostic
ole of preprocedural Thrombolysis In Myocardial Infarc-
ion (TIMI) flow in patients with STEMI undergoing
rimary angioplasty.
ETHODS
ur population consisted of 1,791 patients with STEMI
reated by primary angioplasty at our institution from 1994
o 2001, for whom complete one-year follow-up data were
vailable. Informed consent was obtained from each patient
efore angiography. All patients presenting within 6 h from
ymptom onset, or between 6 and 24 h if they had
ontinuous symptoms and signs of ischemia, were included
8). All patients received aspirin (500 mg) and heparin
10,000 IU) intravenously before the procedure. After the
From the ISALA Klinieken, Hospital De Weezenlanden, Zwolle, the Netherlands.
Manuscript received May 27, 2003; revised manuscript received September 20,s003, accepted November 26, 2003.rocedure, all patients received aspirin and additional war-
arin for three months (before 1996) or ticlopidine (1996 to
999) or clopidogrel for one month (1999 to 2001), in case
f stent implantation. Because the benefit of glycoprotein
Ib/IIIa inhibitors has only been shown recently (9), only
% of our patients received this drug.
Patients were classified according to preprocedural TIMI
ow (TIMI flow grade 0 to 1, 2, or 3).
According to the TIMI risk score (10), patients were
tratified into low- and high-risk groups. Variables included
n this score were age, Killip class I, anterior infarction,
ime to treatment, history of hypertension and/or diabetes
nd/or preinfarction angina, systolic blood pressure, weight,
nd heart rate. A risk score 4 was used to identify the
igh-risk population (10).
ngiographic data analysis. All angiograms were reviewed
y an independent core laboratory (Diagram, Zwolle, the
etherlands), which was blinded to all data apart from the
oronary angiograms. Myocardial blush grade (MBG),
IMI flow, and procedural success were assessed as previ-
usly described (11). Residual stenosis was visually assessed.
rocedural success was defined as postprocedural TIMI flow
rade 3 and residual stenosis 50%.
nzymatic infarct size. Enzymatic infarct size was calcu-
ated, as previously described, by cumulative enzyme release
LDHQ48) from serial measurements up to 48 h after
ymptom onset (12).
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Preprocedural Flow and Mortality in Primary PCI April 21, 2004:1363–7eft ventricular function. Before hospital discharge, left
entricular ejection fraction (EF) was measured by radionu-
lide ventriculography. The multiple-gated equilibrium
ethod was used after in vivo labeling of patients’ red blood
ells with technetium-99m pertechnetate.
ollow-up. Records of patients who visited our outpatient
linic were reviewed. For all other patients, information was
btained from the patient’s general physician or by a direct
elephone interview with the patient. No patient was lost to
ollow-up.
tatistical analysis. Statistical analysis was performed with
he SPSS version 10.0 statistical package. Analysis of
ariance and the chi-square test were used for continuous
nd categorical variables, respectively. Bonferroni’s correc-
ion was applied in case of multiple comparisons. The
ifference in event rates between groups during the
ollow-up period was assessed by the Kaplan-Meier
ethod, using the log-rank test.
Two multivariate analyses were performed by using the
ox proportional hazards method: one including the whole
opulation and one restricted to high-risk patients. The
Abbreviations and Acronyms
CI  confidence interval
EF  ejection fraction
MBG  myocardial blush grade
OR  odds ratio
STEMI  ST-segment elevation myocardial infarction
TIMI  Thrombolysis In Myocardial Infarction
Table 1. Demographic, Clinical, and Angiogra
TIMI Flow
0–1 (n  1,
Age (yrs) 60  11
Male gender (%) 80.1
Diabetes (%) 8.1
Previous infarction (%) 11.5
Anterior infarction or LBBB (%) 49.3
Killip class I (%) 87.2
Ischemic time (min) 214  12
Multivessel disease (%) 55.7
Post-TIMI flow grade 3 (%) 89
Procedural success (%) 87.9
MBG 2–3* (%) 71.5
Stent (%) 48.9
Predischarge ejection fraction† (%) 43  11
LDHQ48‡ (U/l) 2,045  1,6
Medical therapy at discharge
Beta-blockers (%) 83.9
Statin (%) 44.5
ACE inhibitors (%) 55.3
Calcium antagonist (%) 3
Ticlopidine or clopidrogel (%) 25.9
*Data available in 1,771 patients, †1,143 patients, and ‡1,069
of patients. The following p values were adjusted by Bonfer
TIMI flow grade 0–1, ¶p  0.005 vs. TIMI flow grade 0–
LBBB  left bundle branch block; TIMI  Thrombol
LDHQ48  enzymatic infarct size from serial measurements of lacollowing variables were entered in the multivariate analysis
hen they were available from all patients and were signif-
cantly related to mortality on univariate analysis: age,
ender, diabetes, hypercholesterolemia, smoking, family
istory of coronary artery disease, hypertension, previous
yocardial infarction, previous revascularization, previous
erebrovascular accident, quartiles of inclusion period, in-
arct location, time to treatment, door-to-balloon time,
illip class at presentation, preprocedural and postproce-
ural TIMI flow, angiographic evidence of collateral circu-
ation, multivessel disease, procedural success, and stent use.
ESULTS
emographic, clinical, and angiographic characteristics ac-
ording to preprocedural TIMI flow are reported in Table 1.
atients with better preprocedural flow had a lower preva-
ence of multivessel disease, a higher prevalence of anterior
nfarction, and better postprocedural TIMI flow and MBG,
ith a subsequently smaller enzymatic infarct size and better
redischarge EF. Statin therapy was more common in
atients with preprocedural TIMI flow grade 3, whereas the
pposite was observed for angiotensin-converting enzyme
nhibitors.
A total of 103 patients (5.8%) had died by one year. No
ifference was observed between stent and balloon angio-
lasty (5.2% vs 6.1%, p  NS). As depicted in Figure 1, the
ortality rate increased significantly from preprocedural
IMI flow grade 0 to 1 to 3 (odds ratio [OR] 1.38, 95%
onfidence interval [CI] 1.02 to 1.94; p  0.05). As
Characteristics According to Preprocedural
TIMI Flow Grade
2 (n  217) 3 (n  253) p Value
60  11 60  12 NS
77 77.1 NS
7.4 12.3 NS
11.5 10.7 NS
56.7 57.7 0.012
89.9 91.7 NS
216  118 215  210 NS
50.7 46.2§ 0.014
95.4§ 93.7 0.002
94.1§ 92.9 0.005
86¶ 84¶ 0.001
52.1 52.6 NS
44  11 47  11¶ 0.001
1,350  1,152¶ 951  971¶ 0.001
87 88.9 NS
53.7 54.5¶ 0.001
46.6 37.3¶ 0.001
2.2 7.6 NS
26.7 31.2 NS
ts. Data are presented as the mean value SD or percentage
correction for multiple (n  3) comparisons: §p  0.05 vs.
0.05 vs. TIMI flow grade 2.
Myocardial Infarction; MBG  myocardial blush grade;phic
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April 21, 2004:1363–7 Preprocedural Flow and Mortality in Primary PCIeported in Table 2, preprocedural TIMI flow was not an
ndependent predictor of one-year mortality.
reprocedural TIMI flow and mortality in low- and
igh-risk patients. The relationship between preproce-
ural flow and mortality was also investigated in high- and
ow-risk patients, according to the TIMI risk score. A
igh-risk population of 560 patients (31.3%) and a low-risk
opulation of 1,231 patients (68.7%) were identified, with
ne-year mortality rates of 14.5% and 1.8%, respectively
OR 7.43, 95% CI 4.59 to 12.01; p  0.0001).
Preprocedural TIMI flow was significantly related to
ne-year mortality only in high-risk patients (OR 1.86, 95%
I 1.15 to 2.99; p  0.01) (Fig. 1). In these patients, the
ifference in outcome was evident at 30 days and persisted
ntil one-year follow-up, with the best outcome observed in
atients with preprocedural TIMI flow grade 3 (OR 0.26,
5% CI 0.08 to 0.83; p  0.01 vs. TIMI flow grade 0 to 2)
Fig. 2). As depicted in Figure 3, preprocedural TIMI flow
rade 3 in high-risk patients was associated with a better
utcome in both patients who presented early (4 h) and in
hose who presented late (4 h), as compared with prepro-
edural TIMI flow grade 2. The mortality rate remained
table across the study period and was comparable between
atients treated with a stent or balloon (Fig. 3). On
ultivariate analysis performed in high-risk patients (Table
), preprocedural TIMI flow grade 0 to 2 was an indepen-
igure 1. Bar graphs show the relationship between preprocedural Throm-
olysis In Myocardial Infarction (TIMI) flow and one-year mortality in all
atients, as well as in low- and high-risk patients. Black bars TIMI flow
rade 0 to 1; gray bars  grade 2; white bars  grade 3.
able 2. Multiple Regression Analysis for Predictors of One-
ear Mortality
Variable OR (95% CI) p Value
illip class I 5.27 (3.4–8.1)  0.0001
ge (70 yrs) 2.98 (1.9–4.5)  0.0001
ost-TIMI flow grade 0–2 2.96 (1.84–4.71)  0.0001
nterior infarction 2.13 (1.34–3.37) 0.001
ultivessel disease 2.34 (1.42–3.8) 0.001
ymptom onset to balloon (4 h) 1.55 (1.01–2.4) 0.046
I  confidence interval; OR  odds ratio; TIMI  Thrombolysis In Myocardial
tnfarction.ent predictor of one-year mortality (OR 3.19, 95% CI 1.01
o 10.17; p  0.05).
ISCUSSION
he main finding of the present study is that preprocedural
IMI flow grade 3 is an independent predictor of one-year
urvival in high-risk patients with STEMI undergoing
echanical reperfusion.
reprocedural TIMI flow and mortality in STEMI pa-
ients. Several explanations may account for the potential
mpact of preprocedural TIMI flow on outcome in patients
ith STEMI treated by primary angioplasty. As demon-
trated in animal models (13), the duration of coronary
cclusion is a main determinant of myocardial infarct size.
hus, late reperfusion is expected to result in less myocardial
alvage and, conceivably, higher mortality, as compared with
arly reperfusion, even when optimal mechanical reperfu-
ion is applied. Furthermore, a delay in reperfusion may be
ssociated with an older, organized intracoronary thrombus,
n comparison with early reperfusion. This may result in a
igher incidence of distal embolization with less postproce-
ural TIMI flow grade 3 and poor myocardial perfusion—
ll major predictors of mortality in STEMI (11,14). In our
tudy, patients with better preprocedural flow showed a
igher rate of postprocedural TIMI flow grade 3 and MBG
to 3.
Supporting the prognostic role of preprocedural flow in
rimary angioplasty, Stone et al. (15) found only preproce-
ural but not postprocedural TIMI flow grade 3 to be an
ndependent predictor of mortality. The prognostic impor-
ance of preprocedural reperfusion has also been reported by
rodie et al. (16). In a cohort of 1,490 patients treated by
rimary angioplasty, they found preprocedural TIMI flow
rade 2 to 3 to be associated with the amount of cardiac
nzyme release, EF, and mortality on univariate analysis.
he relationship between preprocedural flow and outcome
as not studied in the multivariate analysis. In fact, the
rognostic role of preprocedural flow may be overridden by
he high rate of postprocedural TIMI flow grade 3 obtained
n patients treated by primary angioplasty, as suggested by
he absence of a relationship between time to treatment and
ortality found by previous authors (17,18).
Consistent with Brodie et al. (16), we found a significant
elationship between preprocedural TIMI flow and enzy-
atic infarct size and predischarge EF. Despite the same
ate of postprocedural TIMI flow grade 3 and MBG 2 to 3,
atients with preprocedural TIMI flow grade 3 had a
maller enzymatic infarct size and better predischarge EF, as
ompared with patients with preprocedural TIMI flow
rade 2.
In contrast to previous reports, we investigated the role of
reprocedural TIMI flow according to the patient’s risk
rofile at presentation, because it is conceivable that early
ecanalization, by increasing myocardial salvage, may par-
icularly affect the outcome of high-risk patients. In fact,
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Preprocedural Flow and Mortality in Primary PCI April 21, 2004:1363–7hen we analyzed one-year mortality, we found preproce-
ural TIMI flow grade 3 to be an independent predictor of
utcome only in high-risk patients. Preprocedural TIMI
ow grade 3 was associated with a better outcome in both
atients who presented early (4 h) and in those who
resented late (4 h), whereas in patients with preproce-
ural TIMI flow grade 2, a further impairment in out-
ome was observed in patients who presented late (Fig. 3).
igure 2. Kaplan-Meier survival curves according to preprocedural Throm
Log-rank statistic  9.3, p  0.01 vs. TIMI flow grade 0 to 2.
igure 3. Relationship between preprocedural Thrombolysis In Myocar-
ial Infarction (TIMI) flow and mortality in high-risk patients, with
elative risk and 95% confidence interval (CI), according to the study
nclusion period, ischemic time, and stent use. Aupporting the role of ischemic time in primary angioplasty,
ntoniucci et al. (7) found that total ischemic time was
elated to mortality only in high-risk patients.
All these data demonstrate that in patients with STEMI
ndergoing angioplasty, preprocedural TIMI flow is a major
ndependent predictor of mortality in high-risk patients.
tudy limitations. Although the TIMI risk score was
erived from patients treated by thrombolysis, the included
ariables still represent major independent predictors of
utcome in patients treated by primary angioplasty (19,20).
n fact, the TIMI risk score was also able to identify a
igh-risk population in our study.
Some variables in our study, particularly enzymatic infarct
ize and predischarge EF, were not available from all
atients, and therefore could not be included in the multi-
ariate analysis. However, it is clear that the benefits of
reprocedural TIMI flow grade 3 on mortality are related to
ore extensive myocardial salvage, and thus better EF and
ore limited enzymatic infarct size.
Although potential changes in medical therapy and an
is In Myocardial Infarction (TIMI) flow in low- and high-risk patients.
able 3. Multivariate Analysis for Predictors of One-Year
ortality in High-Risk Patients
Variable OR (95% CI) p Value
illip class I 4.12 (2.41–7.04) 0.0001
ost-TIMI flow grade 0–2 2.85 (1.72–4.72) 0.0001
ge 70 yrs 2.29 (1.38–3.8) 0.0001
ultivessel disease 2.05 (1.13–3.7) 0.018
reprocedural TIMI flow grade 0–2 3.19 (1.01–10.17) 0.049bolysbbreviations as in Table 2.
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April 21, 2004:1363–7 Preprocedural Flow and Mortality in Primary PCIncreasing rate of stenting may have occurred across our
tudy time, with an important impact on clinical outcome,
he prognostic role of preprocedural TIMI flow grade 3 was
table across the study period (Fig. 3).
linical implications and conclusions. Although primary
ngioplasty has been demonstrated to be superior to throm-
olytic therapy, several areas for improvement still remain.
ransportation to tertiary centers with angioplasty facilities
as been shown to be safe and feasible (21). However, the
ime delay due to transportation remains a major drawback
o primary angioplasty, particularly in high-risk patients.
he results of our study suggest that all efforts should be
ade to obtain optimal restoration of antegrade flow as
arly as possible during transportation. Although the inde-
endent predictive value of preprocedural TIMI flow grade
in high-risk patients would argue that it is independent of
he time delay to treatment, early drug administration has
een shown to be associated with higher rates of vessel
atency and aborted infarction (22,23). Therefore, the
lliance between early pharmacologic therapies and angio-
lasty for acute myocardial infarction, the so-called “facili-
ated angioplasty,” may be attractive and is currently an area
f great interest (24–26). Further trials are needed to
nvestigate this combined approach, particularly in high-risk
atients who will, as demonstrated by our data, benefit most
rom early and optimal recanalization.
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